Abstract: An embodiment of a radio-frequency (RF) device includes at least one transistor, a package, and a surface-mountable capacitor. The package contains the at least one transistor and includes at least one termination. The surface-mountable capacitor is coupled in a shunt configuration between the at least one transistor and a power supply terminal of the device to decouple the at least one transistor from a power supply.

Abstract: In aspects of the present application, circuitry for storing data is provided including a static random access memory (SRAM) circuit operable to store data in an array of SRAM cell circuits arranged in rows and columns, each SRAM cell coupled to a pair of complementary bit lines disposed along the columns of SRAM cells circuits, and one or more precharge circuits in the SRAM memory circuit coupled to one or more pairs of the complementary bit lines and operable to charge the pairs of complementary bit lines to a precharge voltage, responsive to a precharge control signal. The precharge control signal within the SRAM circuit is operable to cause coupling transistors within the SRAM circuit to couple a pair of complementary bit lines to the precharge voltage responsive to mode signals output from a memory controller circuit external to the SRAM circuit, indicating a bitline precharge is to be performed.

Abstract: Disclosed herein is a method and an electronic device. The electronic device may include a display and a transmission/reception module, and at least one processor. The processor may implemented the method, including receiving a first message and a second message to be transmitted to an external electronic device, generating, by at least one processor, a combined message including both the first message and the second message, and transmitting, by a transmission/reception module, the combined message to the external electronic device.

Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.

Abstract: The present invention provides for bioavailable oral dosage forms containing esters of 17-hydroxyprogesterone as well as related methods. The oral dosage forms can be formulated for pregnancy support and can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. In another embodiment, a pharmaceutically acceptable oral dosage form for pregnancy support is provided. The pharmaceutically acceptable oral dosage can include a therapeutically effective amount of an ester of 17-hydroxyprogesterone and a pharmaceutically acceptable carrier. The oral dosage form can, when measured using a USP Type-II dissolution apparatus in 900 mL of deionized water with 0.5 (w/v) of sodium lauryl sulfate at 50 RPM at 37° C., release at least 20 wt % of the dose of the ester of 17-hydroxyprogesterone after 60 minutes, or in the alternative release at least 20 wt % more after 60 minutes than an equivalently dosed oral dosage form without the carrier.

Abstract: The present disclosure is drawn to pharmaceutical compositions and oral dosage capsules containing testosterone undecanoate, as well as related methods. The capsule includes a capsule shell and a capsule fill. The capsule fill can include a solubilizer and about 14 wt % to about 35 wt % testosterone undecanoate based on the total capsule fill. The oral dosage capsule is such that when a single oral administration to a male subject of one or more capsules with a total testosterone undecanoate daily dose of about 350 mg to about 650 mg it provides a ratio of serum testosterone Cmax to serum testosterone Cave of about 2.7 or less. In yet another embodiment, a method for providing a serum concentration of testosterone within a target serum testosterone concentration Cave range for a male subject is provided.

Abstract: In an integrated clock gating (ICG) cell a latch is coupled to a NOR gate. The NOR gate receives an enable signal. The latch is configured to generate a latch output in response to the state of the enable signal. The latch includes a tri-state inverter. A NAND gate is coupled to the latch and the NAND gate is configured to generate an inverted clock signal in response to the latch output and a clock input.

Abstract: Methods and systems are provided for global server load balancing in a communication network using a global site selector and an application control engine in communication with the global site selector, in which the application control engine notifies the global site selector in response to a state change for a virtual internet protocol (VIP) address. Keepalive methods generally rely on periodically polling VIP addresses to check whether they are in an ONLINE or OFFLINE state. A minimum interval between two keepalives can be as long as 40 seconds, during which, without a mechanism to reflect state change to the load balancer in real time, if a VIP address changes state (e.g., VIP address failure), a customer can experience network outage during the time interval. Embodiments provide a mechanism to reflect, in real time, the current VIP address state to a global server load balancer to reduce failure detection time.

Abstract: Systems and methods are disclosed for verifying a vehicle component. In various embodiments, a system for verifying a vehicle component may comprise a near-to-eye (NTE) display system that includes an NTE tracking controller, a controller communicatively coupled to the NTE tracking controller, and a component database communicatively coupled to the controller. The controller may be configured to receive component data from the component database and communicate the component data to the NTE tracking controller based upon focus data, where the focus data is based upon a head position of an operator.

Abstract: The method and system make it possible for devices that may not be co-located to capture information such as images, videos, text, audio, speech, location, etc. and create a composite image therefrom. The method and system includes a session initiated by one of the devices to other devices through a central server and/or by peer-to-peer network to synchronize the capture of information across all the devices. The method and system makes it possible to either synchronize the capture of information at each device or allow for preset time differences when each device captures information or allow for such time differences to be random or otherwise uncontrolled.

Abstract: The invention relates to the compounds of formula I, formula II, formula III and formula IV or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III or formula IV and methods for the treatment of mucositis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of mucositis and oral mucosal inflammatory or oral infectious diseases.

Abstract: A method of implanting and securing an implantable flow connector in a body of a patient for providing communication of a first space within the body of the patient with a second space within the body of the patient. The method includes providing a flow connector having a lumen having a first orifice and a second orifice, inserting a retention device into the first space within the body, subsequently inserting the flow connector through an opening in the retention device so the second portion of the flow connector extends into the first space within the body and placing the second space within the body over the retention device.

Abstract: Flow cytometer systems are provided having intermediate angle scatter detection capability. In some aspects, systems are provided that include an intermediate angle scatter (IAS) light detector positioned to measure intermediate angle scatter emitted from a flow cytometer. The system further includes a mask disposed across a portion of the IAS light detector and positioned between the flow cell and the IAS light detector to cover at least a central portion of the IAS light detector so as to block a diffraction pattern observed at the detector. In some instances, the diffraction pattern is created by a flat beam profile irradiating the sample. Methods are also provided for configuring a flow cytometer to block a diffraction pattern created by (1) a flat laser beam profile irradiating a flow cytometer liquid sample, or (2) a mismatched index of refraction between a sheath fluid and a liquid sample in a flow cytometer.

Abstract: The invention relates to the compounds of formula I and formula II or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I or formula II; and methods for treating or preventing multiple sclerosis may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of multiple sclerosis and psoriasis.

Abstract: Techniques are described for applying double experimental (EXP) quality of service (QoS) markings to Multiprotocol Label Switching (MPLS) packets. According to the techniques, an edge router of an MPLS network is configured to map a Differentiated Services Code Point (DSCP) marking for customer traffic to at least two EXP fields of at least two different labels included in a MPLS packet encapsulating the customer traffic. In this way, the edge router may map the full DSCP marking across the first and second EXP fields to provide full resolution QoS for the customer traffic over the MPLS network. The techniques also include a core router of an MPLS network configured to identify a QoS profile for a received MPLS packet based on a combination of a first EXP field of a first label and a second EXP field of a second label included in the MPLS packet.

Abstract: A device has a base with a mounting surface with a length and a stack, the stack having a diameter smaller than the length and fastened to the mounting surface. The stack may have a plurality of stack conductive layers in addition to a plurality of insulating layers that separate each of the plurality of stack conductive layers. The stack conductive layers may be separated in a manner that aligns them with corresponding printed circuit board conductive layers when the stack portion of the device is inserted into an aperture in a printed circuit board.

Abstract: Methods and apparatus of using customizable templates in process control systems are disclosed. An example method includes initializing a first process control device associated with a first protocol based on a template file and a first parameter definition file. The template file includes global variables and associated values. The first parameter definition file defines a relationship between the global variables and first local variables of at least one of the first process control device or the first protocol. The example method also includes initializing a second process control device associated with a second protocol based on the template file and a second parameter definition file. The second parameter definition file defines a relationship between the global variables and second local variables of at least one of the second process control device or the second protocol. The first protocol is different from the second protocol.

Abstract: In some embodiments, a request for a content object may be received as a data packet. Upon determining that the content object is not cached, an element of the data packet may be modified and the modified data packet may be forwarded toward a content provider of the content object.

Abstract: A circuit breaker and a method of developing the current limiting circuit breaker are described. The circuit breaker includes a carrier assembly to supply current to a circuit through a fixed contact in a first operative state. The carrier assembly includes a latch pin to move responsive to a force transferred to the latch pin as a result of a fault condition in the circuit, a cam assembly in contact with the latch pin to move responsive to movement of the latch pin, and a movable contact coupled to the cam assembly, the movable contact breaking the physical contact with the fixed contact to put the circuit breaker in a second operative state. The circuit breaker also includes a mechanism to move the carrier assembly responsive to a signal indicative of the fault condition to put the circuit breaker in a third operative state.